AT-51 PHASE I STUDY OF PANOBINOSTAT AND FRACTIONATED STEREOTACTIC RE-IRRADIATION THERAPY (FSRT) FOR RECURRENT HIGH GRADE GLIOMAS

PURPOSE: To perform a phase I study to evaluate the safety, and tolerability of panobinostat, an HDAC inhibitor, when combined with fractionated stereotactic re-irradiation therapy (FSRT) for recurrent gliomas. METHODS: Patients with recurrent gliomas (WHO grade II-IV) were eligible for this trial....

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Shi, Wenyin, Lawrence, Yaacov Richard, Werner-wasik, Maria, Evans, James, Andrews, David, Glass, Jon, Kim, Lyndon, Ad, Voichita Bar, Moshel, Yaron, Judy, Kevin, Farrell, Christopher, Simon, Nicole, Dicker, Adam
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2014
Sujets:
Adult Clinical Trials
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217831/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.50
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires